Literature DB >> 34584243

Glial and myeloid heterogeneity in the brain tumour microenvironment.

Brian M Andersen1,2, Camilo Faust Akl1, Michael A Wheeler1,3, E Antonio Chiocca4, David A Reardon2, Francisco J Quintana5,6.   

Abstract

Brain cancers carry bleak prognoses, with therapeutic advances helping only a minority of patients over the past decade. The brain tumour microenvironment (TME) is highly immunosuppressive and differs from that of other malignancies as a result of the glial, neural and immune cell populations that constitute it. Until recently, the study of the brain TME was limited by the lack of methods to de-convolute this complex system at the single-cell level. However, novel technical approaches have begun to reveal the immunosuppressive and tumour-promoting properties of distinct glial and myeloid cell populations in the TME, identifying new therapeutic opportunities. Here, we discuss the immune modulatory functions of microglia, monocyte-derived macrophages and astrocytes in brain metastases and glioma, highlighting their disease-associated heterogeneity and drawing from the insights gained by studying these malignancies and other neurological disorders. Lastly, we consider potential approaches for the therapeutic modulation of the brain TME.
© 2021. Springer Nature Limited.

Entities:  

Mesh:

Year:  2021        PMID: 34584243      PMCID: PMC8616823          DOI: 10.1038/s41568-021-00397-3

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN: 1474-175X            Impact factor:   69.800


  243 in total

1.  Interrogation of the Microenvironmental Landscape in Brain Tumors Reveals Disease-Specific Alterations of Immune Cells.

Authors:  Florian Klemm; Roeltje R Maas; Robert L Bowman; Mara Kornete; Klara Soukup; Sina Nassiri; Jean-Philippe Brouland; Christine A Iacobuzio-Donahue; Cameron Brennan; Viviane Tabar; Philip H Gutin; Roy T Daniel; Monika E Hegi; Johanna A Joyce
Journal:  Cell       Date:  2020-05-28       Impact factor: 41.582

2.  Single-Cell Mapping of Human Brain Cancer Reveals Tumor-Specific Instruction of Tissue-Invading Leukocytes.

Authors:  Ekaterina Friebel; Konstantina Kapolou; Susanne Unger; Nicolás Gonzalo Núñez; Sebastian Utz; Elisabeth Jane Rushing; Luca Regli; Michael Weller; Melanie Greter; Sonia Tugues; Marian Christoph Neidert; Burkhard Becher
Journal:  Cell       Date:  2020-05-28       Impact factor: 41.582

3.  Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain.

Authors:  Hussein A Tawbi; Peter A Forsyth; Alain Algazi; Omid Hamid; F Stephen Hodi; Stergios J Moschos; Nikhil I Khushalani; Karl Lewis; Christopher D Lao; Michael A Postow; Michael B Atkins; Marc S Ernstoff; David A Reardon; Igor Puzanov; Ragini R Kudchadkar; Reena P Thomas; Ahmad Tarhini; Anna C Pavlick; Joel Jiang; Alexandre Avila; Sheena Demelo; Kim Margolin
Journal:  N Engl J Med       Date:  2018-08-23       Impact factor: 91.245

4.  COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells.

Authors:  Mitsugu Fujita; Gary Kohanbash; Wendy Fellows-Mayle; Ronald L Hamilton; Yoshihiro Komohara; Stacy A Decker; John R Ohlfest; Hideho Okada
Journal:  Cancer Res       Date:  2011-02-15       Impact factor: 12.701

5.  Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma.

Authors:  Peter E Fecci; Duane A Mitchell; John F Whitesides; Weihua Xie; Allan H Friedman; Gary E Archer; James E Herndon; Darell D Bigner; Glenn Dranoff; John H Sampson
Journal:  Cancer Res       Date:  2006-03-15       Impact factor: 12.701

6.  Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial.

Authors:  Sarah B Goldberg; Scott N Gettinger; Amit Mahajan; Anne C Chiang; Roy S Herbst; Mario Sznol; Apostolos John Tsiouris; Justine Cohen; Alexander Vortmeyer; Lucia Jilaveanu; James Yu; Upendra Hegde; Stephanie Speaker; Matthew Madura; Amanda Ralabate; Angel Rivera; Elin Rowen; Heather Gerrish; Xiaopan Yao; Veronica Chiang; Harriet M Kluger
Journal:  Lancet Oncol       Date:  2016-06-03       Impact factor: 41.316

Review 7.  T-Cell based therapies for overcoming neuroanatomical and immunosuppressive challenges within the glioma microenvironment.

Authors:  Darwin Kwok; Hideho Okada
Journal:  J Neurooncol       Date:  2020-03-17       Impact factor: 4.130

8.  Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study.

Authors:  Georgina V Long; Victoria Atkinson; Serigne Lo; Shahneen Sandhu; Alexander D Guminski; Michael P Brown; James S Wilmott; Jarem Edwards; Maria Gonzalez; Richard A Scolyer; Alexander M Menzies; Grant A McArthur
Journal:  Lancet Oncol       Date:  2018-03-27       Impact factor: 41.316

9.  Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma.

Authors:  Sangeeta Goswami; Thomas Walle; Andrew E Cornish; Sreyashi Basu; Swetha Anandhan; Irina Fernandez; Luis Vence; Jorge Blando; Hao Zhao; Shalini Singh Yadav; Martina Ott; Ling Y Kong; Amy B Heimberger; John de Groot; Boris Sepesi; Michael Overman; Scott Kopetz; James P Allison; Dana Pe'er; Padmanee Sharma
Journal:  Nat Med       Date:  2019-12-23       Impact factor: 53.440

10.  Inhibitory CD161 receptor identified in glioma-infiltrating T cells by single-cell analysis.

Authors:  Nathan D Mathewson; Orr Ashenberg; Itay Tirosh; Simon Gritsch; Elizabeth M Perez; Sascha Marx; Livnat Jerby-Arnon; Rony Chanoch-Myers; Toshiro Hara; Alyssa R Richman; Yoshinaga Ito; Jason Pyrdol; Mirco Friedrich; Kathrin Schumann; Michael J Poitras; Prafulla C Gokhale; L Nicolas Gonzalez Castro; Marni E Shore; Christine M Hebert; Brian Shaw; Heather L Cahill; Matthew Drummond; Wubing Zhang; Olamide Olawoyin; Hiroaki Wakimoto; Orit Rozenblatt-Rosen; Priscilla K Brastianos; X Shirley Liu; Pamela S Jones; Daniel P Cahill; Matthew P Frosch; David N Louis; Gordon J Freeman; Keith L Ligon; Alexander Marson; E Antonio Chiocca; David A Reardon; Aviv Regev; Mario L Suvà; Kai W Wucherpfennig
Journal:  Cell       Date:  2021-02-15       Impact factor: 66.850

View more
  11 in total

Review 1.  Ribosomal proteins induce stem cell-like characteristics in glioma cells as an "extra-ribosomal function".

Authors:  Takuichiro Hide; Ichiyo Shibahara; Madoka Inukai; Ryota Shigeeda; Yuki Shirakawa; Hirofumi Jono; Naoki Shinojima; Akitake Mukasa; Toshihiro Kumabe
Journal:  Brain Tumor Pathol       Date:  2022-05-05       Impact factor: 3.298

2.  Multicellular biomarkers of drug resistance as promising targets for glioma precision medicine and predictors of patient survival.

Authors:  Yuting Lu; Yongzhao Shao
Journal:  Cancer Drug Resist       Date:  2022-06-02

Review 3.  The Oncogenesis of Glial Cells in Diffuse Gliomas and Clinical Opportunities.

Authors:  Qiyuan Zhuang; Hui Yang; Ying Mao
Journal:  Neurosci Bull       Date:  2022-10-13       Impact factor: 5.271

4.  ZNF395 facilitates macrophage polarization and impacts the prognosis of glioma.

Authors:  Feng Xiao; Jie Shen; Lihui Zhou; Zebin Fang; Yuxiang Weng; Chao Zhang; Luyuan Zhang; Xin Huang; Renya Zhan
Journal:  Am J Cancer Res       Date:  2022-09-15       Impact factor: 5.942

Review 5.  The immunology of low-grade gliomas.

Authors:  Alexander F Haddad; Jacob S Young; Jun Yeop Oh; Hideho Okada; Manish K Aghi
Journal:  Neurosurg Focus       Date:  2022-02       Impact factor: 4.332

Review 6.  Tumor-Associated Macrophages in Gliomas-Basic Insights and Treatment Opportunities.

Authors:  Johannes K Andersen; Hrvoje Miletic; Jubayer A Hossain
Journal:  Cancers (Basel)       Date:  2022-03-04       Impact factor: 6.639

Review 7.  Mechanical Properties in the Glioma Microenvironment: Emerging Insights and Theranostic Opportunities.

Authors:  Adip G Bhargav; Joseph S Domino; Roukoz Chamoun; Sufi M Thomas
Journal:  Front Oncol       Date:  2022-01-21       Impact factor: 6.244

Review 8.  Challenges and Opportunities for Immunotherapeutic Intervention against Myeloid Immunosuppression in Glioblastoma.

Authors:  Mark A Exley; Samantha Garcia; Amelia Zellander; Jenny Zilberberg; David W Andrews
Journal:  J Clin Med       Date:  2022-02-18       Impact factor: 4.241

9.  The glioblastoma multiforme tumor site promotes the commitment of tumor-infiltrating lymphocytes to the TH17 lineage in humans.

Authors:  Meike Mitsdoerffer; Lilian Aly; Melanie Barz; Thomas Engleitner; Christopher Sie; Claire Delbridge; Gildas Lepennetier; Rupert Öllinger; Monika Pfaller; Benedikt Wiestler; Roland Rad; Bernhard Meyer; Benjamin Knier; Friederike Schmidt-Graf; Jens Gempt; Thomas Korn
Journal:  Proc Natl Acad Sci U S A       Date:  2022-08-15       Impact factor: 12.779

10.  MS4A6A is a new prognostic biomarker produced by macrophages in glioma patients.

Authors:  Chunyu Zhang; Haitao Liu; Yinqiu Tan; Yang Xu; Yuntao Li; Shiao Tong; Sheng Qiu; Qianxue Chen; Zhongzhou Su; Daofeng Tian; Wei Zhou; Chunlong Zhong
Journal:  Front Immunol       Date:  2022-08-09       Impact factor: 8.786

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.